Intravitreal bevacizumab (Avastin) for retinal angiomatous proliferation

Catherine B. Meyerle, K. Bailey Freund, Diana Iturralde, Richard F. Spaide, John A. Sorenson, Jason S. Slakter, James M. Klancnik, Yale L. Fisher, Michael J. Cooney, Lawrence A. Yannuzzi

Research output: Contribution to journalReview articlepeer-review

79 Scopus citations


OBJECTIVE: To evaluate the short-term visual acuity and anatomic responses after intravitreal bevacizumab (Avastin, Genentech) treatment in patients with retinal angiomatous proliferation (RAP). METHODS: The authors conducted a retrospective review of consecutive patients with newly diagnosed or recurrent RAP treated with intravitreal bevacizumab (1.25 mg) during a 3-month period. Complete ocular examination was performed at baseline and follow-up visits. Interval data were analyzed statistically at 1 and 3 months follow-up. RESULTS: Twenty-three eyes of 23 patients underwent intravitreal bevacizumab treatment. The mean age of patients was 81.1 years, median baseline visual acuity of treated eyes was 20/80 (range 20/25-20/800), and mean baseline central macular thickness was 335 μm (optical coherence tomography was available for 22 eyes). Nine eyes had retinal pigment epithelial detachments (PEDs) at baseline. At 1-month follow-up, the median acuity improved to 20/60 (range 20/30-20/400) (P < 0.001), mean central macular thickness decreased to 202 μm (P < 0.001), and PED was present in only 2 eyes (P = 0.016). Seven of 23 eyes at 1 month (30.4%) had improved visual acuity, defined as halving of the visual angle, and no eyes had worse acuity, defined as doubling of the visual angle. Of the 17 eyes available for 3-month follow-up, 5 eyes (29.4%) had better visual acuity, 1 eye (5.9%) had worse acuity, and the remaining 11 (64.7%) had the same acuity. The median visual acuity at month 3 was 20/60 (range 20/25-20/400). There were no thromboembolic phenomena, endophthalmitis cases, retinal detachments, or any other adverse events. CONCLUSION: Treatment of RAP with intravitreal bevacizumab during this retrospective review resulted in a significant decrease in macular thickness and improvement or stabilization of visual acuity. Further long-term investigation is warranted given the promising short-term results.

Original languageEnglish (US)
Pages (from-to)451-457
Number of pages7
Issue number4
StatePublished - Apr 1 2007


  • Age-related macular degeneration
  • Bevacizumab
  • Retinal angiomatous proliferation

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'Intravitreal bevacizumab (Avastin) for retinal angiomatous proliferation'. Together they form a unique fingerprint.

Cite this